文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 2013年中抗体药物回顾
侵权投诉

2013年中抗体药物回顾

Table 1. therapeutic antibodies in Phase 3 clinical studies of non-cancer indications

Sponsoring companyINN or code nameMolecular typeTarget(s)Current

phasePhase 3 indications

AmgenEvolocumab, AMG 145Human igG2PcsK-9Phase 3Hypercholesterolemia;

hyperlipidemia

regeneron; sanofiAlirocumab,Hypercholesterolemia; acute

rEGn-727, sAr236553Human igG1PcsK-9Phase 3coronary syndrome

Amgenromosozumab, Postmenopausal osteopo-

AMG785Humanized igG2sclerostinPhase 3rosis

MerckActoxumab + bezlotox-

umab, MK-3415AHuman igG1c. difficile enterotoxin

A and BPhase 3c. difficile infection

XBiotech, inc.MABp1HumaniL-1 αPhase 3cachexia in cancer patients

Xoma; servierGevokizumabHumanized igG2iL-1 βPhase 3non-infectious uveitis

Asthma; hypereosinophilic

GlaxosmithKlineMepolizumabHumanized igG1iL-5Phase 3syndrome; coPd with eosin-

ophilic bronchitis

tevareslizumabHumanized igG4iL-5Phase 3Eosinophilic asthma

Janssen research &

development LLcsirukumabHuman igG1iL-6Phase 3rheumatoid arthritis

regeneron; sanofisarilumab, sAr153191,

rEGn88Human igG1iL-6r subunit aPhase 3rheumatoid arthritis

Hoffmann-La rocheLebrikizumabHumanized igG4iL-13Phase 3severe asthma

Eli Lilly and co.ixekizumab, LY2439821Humanized igG4iL-17aPhase 3Psoriasis, psoratric arthritis,

plaque psoriasis

rheumatoid or psoriatic

novartis PharmaceuticalssecukinumabHuman igG1iL-17aPhase 3arthritis; ankylosing spondy-

litis; psoriasis

Brodalumab, AMG827, Plaque psoriasis, pustular

Amgen; Kyowa Hakko KirinKHK4827Human igG2iL-17rPhase 3psoriasis and psoriatic eryth-

roderma

Mercktildrakizumab,

MK-3222Humanized igG1iL-23 p19 subunitPhase 3Plaque psoriasis

Eli Lilly and co.tabalumab, LY2127399Human igG4BLysPhase 3sLE

GenentechocrelizumabHumanized igG1cd20Phase 3Multiple sclerosis

UcBEpratuzumabHumanized igG1cd22Phase 3sLE

Hoffmann-LarocheGantenerumabHuman igG1Amyloid bPhase 3Alzheimer disease

Eli Lilly and co.solanezumabHumanized igG1Amyloid bPhase 3Alzheimer disease

note: table compiled from information available as of April 25, 2013. Abbreviations: cd, cluster of differentiation; iL, interleukin; PcsK9, proprotein convertase subtilisin/kexin type; sLE, systemic lupus erythematosus.

200 mg tildrakizumab at week 0 and week 4, and then every Rilotumumab (Amgen) is a human IgG2 targeting human 12 weeks until study end or participant discontinuation. The com-hepatocyte growth factor/scatter factor (HGF/SF) that blocks parator is placebo. In the 54-week NCT01729754 study in the binding of HGF/SF to its receptor MET, thereby inhibiting the same indication, patients receive the same doses of tildrakizumab, MET signaling pathways. The mAb is undergoing evaluation but the study includes 50 mg etanercept as well as placebo as in a Phase 3 study (NCT01697072) of chemotherapy (epirubi-comparators. Both studies are followed by an optional long-term cin, cisplatin and capecitabine) with rilotumumab or placebo safety extension study. The two Phase 3 studies have estimated for untreated advanced MET-positive gastric or gastresopha-primary completion dates of June and July 2015, respectively.geal junction adenocarcinoma. Rilotumumab or placebo is doc.guandang.net mAbs 515©2013 Landes Bioscience. Do not distribute.

上一页第3页

你可能喜欢

  • 药物研发
  • 抗体应用
  • 抗体工程
  • 抗体制备
  • 产业研究报告

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email